BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

394 related articles for article (PubMed ID: 26346137)

  • 1. 18F-FDG PET/CT in the post-operative monitoring of patients with adrenocortical carcinoma.
    Ardito A; Massaglia C; Pelosi E; Zaggia B; Basile V; Brambilla R; Vigna-Taglianti F; Duregon E; Arena V; Perotti P; Penna D; Terzolo M
    Eur J Endocrinol; 2015 Dec; 173(6):749-56. PubMed ID: 26346137
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FDG-PET in adrenocortical carcinoma.
    Becherer A; Vierhapper H; Pötzi C; Karanikas G; Kurtaran A; Schmaljohann J; Staudenherz A; Dudczak R; Kletter K
    Cancer Biother Radiopharm; 2001 Aug; 16(4):289-95. PubMed ID: 11602999
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical value of F18-fluorodeoxyglucose positron emission tomography-computed tomography in patients with non-small cell lung cancer after potentially curative surgery: experience with 241 patients.
    Kanzaki R; Higashiyama M; Maeda J; Okami J; Hosoki T; Hasegawa Y; Takami M; Kodama K
    Interact Cardiovasc Thorac Surg; 2010 Jun; 10(6):1009-14. PubMed ID: 20197344
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of 2-[18F] fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in the post-therapy surveillance of breast cancer.
    Chang HT; Hu C; Chiu YL; Peng NJ; Liu RS
    PLoS One; 2014; 9(12):e115127. PubMed ID: 25517451
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Usefulness 18F-FDG positron emission tomography/computed tomography for detecting recurrence of hepatocellular carcinoma in posttransplant patients.
    Kim YK; Lee KW; Cho SY; Han SS; Kim SH; Kim SK; Park SJ
    Liver Transpl; 2010 Jun; 16(6):767-72. PubMed ID: 20517911
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical utility of F-18 FDG PET/CT in recurrent breast carcinoma.
    Manohar K; Mittal BR; Senthil R; Kashyap R; Bhattacharya A; Singh G
    Nucl Med Commun; 2012 Jun; 33(6):591-6. PubMed ID: 22334135
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fluorodesoxyglucose uptake in the remaining adrenal glands during the follow-up of patients with adrenocortical carcinoma: do not consider it as malignancy.
    Leboulleux S; Deandreis D; Escourrou C; Al Ghuzlan A; Bidault F; Aupérin A; Travagli JP; Lumbroso J; Schlumberger M; Baudin E
    Eur J Endocrinol; 2011 Jan; 164(1):89-94. PubMed ID: 20921280
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of [18F]fluorodeoxyglucose positron emission tomography in evaluating locally recurrent and metastatic adrenocortical carcinoma.
    Mackie GC; Shulkin BL; Ribeiro RC; Worden FP; Gauger PG; Mody RJ; Connolly LP; Kunter G; Rodriguez-Galindo C; Wallis JW; Hurwitz CA; Schteingart DE
    J Clin Endocrinol Metab; 2006 Jul; 91(7):2665-71. PubMed ID: 16621901
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical impact of 18F-FDG-PET in the suspicion of recurrent colorectal cancer based on asymptomatically elevated serum level of carcinoembryonic antigen (CEA) in Taiwan.
    Shen YY; Liang JA; Chen YK; Tsai CY; Kao CH
    Hepatogastroenterology; 2006; 53(69):348-50. PubMed ID: 16795969
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of tumor heterogeneity in treatment-naïve adrenocortical cancer patients using (18)F-FDG positron emission tomography.
    Werner RA; Kroiss M; Nakajo M; Mügge DO; Hahner S; Fassnacht M; Schirbel A; Bluemel C; Higuchi T; Papp L; Zsótér N; Buck AK; Bundschuh RA; Lapa C
    Endocrine; 2016 Sep; 53(3):791-800. PubMed ID: 27138903
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of ¹⁸F-FDG PET/CT for detecting recurrence of medullary thyroid carcinoma.
    Ozkan E; Soydal C; Kucuk ON; Ibis E; Erbay G
    Nucl Med Commun; 2011 Dec; 32(12):1162-8. PubMed ID: 21946617
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical impact of fluorodeoxyglucose-positron emission tomography scan/computed tomography in comparison with computed tomography on the detection of colorectal cancer recurrence.
    Deleau C; Buecher B; Rousseau C; Kraeber-Bodéré F; Flamant M; des Varannes SB; Frampas E; Galmiche JP; Matysiak-Budnik T
    Eur J Gastroenterol Hepatol; 2011 Mar; 23(3):275-81. PubMed ID: 21304319
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical impact of FDG PET-CT in patients with potentially operable metastatic colorectal cancer.
    Briggs RH; Chowdhury FU; Lodge JP; Scarsbrook AF
    Clin Radiol; 2011 Dec; 66(12):1167-74. PubMed ID: 21867996
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Performance of (18)F-FDG PET/CT as a postoperative surveillance imaging modality for asymptomatic advanced gastric cancer patients.
    Lee DY; Lee CH; Seo MJ; Lee SH; Ryu JS; Lee JJ
    Ann Nucl Med; 2014 Oct; 28(8):789-95. PubMed ID: 24965850
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [¹²³I]Iodometomidate imaging in adrenocortical carcinoma.
    Kreissl MC; Schirbel A; Fassnacht M; Haenscheid H; Verburg FA; Bock S; Saeger W; Knoedler P; Reiners C; Buck AK; Allolio B; Hahner S
    J Clin Endocrinol Metab; 2013 Jul; 98(7):2755-64. PubMed ID: 23609836
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 18F-fluorodeoxyglucose positron emission tomography/computed tomography is useful in postoperative follow-up of asymptomatic non-small-cell lung cancer patients.
    Toba H; Sakiyama S; Otsuka H; Kawakami Y; Takizawa H; Kenzaki K; Kondo K; Tangoku A
    Interact Cardiovasc Thorac Surg; 2012 Nov; 15(5):859-64. PubMed ID: 22914804
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High incidence of peritoneal implants in recurrence of intra-abdominal cancer revealed by 18F-FDG PET/CT in patients with increased tumor markers and negative findings on conventional imaging.
    Panagiotidis E; Datseris IE; Exarhos D; Skilakaki M; Skoura E; Bamias A
    Nucl Med Commun; 2012 Apr; 33(4):431-8. PubMed ID: 22293498
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Utility of low dose (18)F-FDG PET-CT in patients with suspected colorectal carcinoma recurrence in conventional diagnostic methods.
    Ochoa-Figueroa MA; Uña-Gorospe J; Allende-Riera A; Cárdenas-Negro JC; Muñoz-Iglesias J; Cabello-García D; De Sequera-Rahola M; Martínez-Gimeno E
    Rev Esp Med Nucl Imagen Mol; 2012 Sep; 31(5):249-56. PubMed ID: 23067526
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Application of 18F-FDG PET/CT scan in following-up of nasopharyngeal carcinoma after radiotherapy].
    Yu DF; Zuo CT; Dai JZ; Dong MJ; Zhao J; Lin XT; Guan YH
    Ai Zheng; 2004 Nov; 23(11 Suppl):1538-41. PubMed ID: 15566675
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 18F-FDG PET/CT for the prediction and detection of local recurrence after radiofrequency ablation of malignant lung lesions.
    Singnurkar A; Solomon SB; Gönen M; Larson SM; Schöder H
    J Nucl Med; 2010 Dec; 51(12):1833-40. PubMed ID: 21078787
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.